By Fineline Cube 
Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.
Fund Details
The Jiansheng Guoxin Taida Equity Investment Fund Partnership aims to invest in strategic emerging industries. The fund’s establishment is subject to final registration with the market supervision and administration authority.
Partners Involved
Key partners include CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., Gongqingcheng Jianxing Investment Partnership, Tianjin Teda International Holdings (Group) Co., Ltd., Tianjin Guoxin No.1 Industrial Development Master Fund Partnership, and CCB Leading Strategic Emerging Industries Development Fund.-Fineline Info & Tech